Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company's core listed products have shown steady sales growth, and the pipeline of research projects is progressing well. In 2024, the company achieved revenue of 1.194 billion yuan, a year-on-year increase of 17.7%, and a net profit attributable to shareholders of 705 million yuan, a year-on-year increase of 139.15% [4][5] - The company has a total of 22 autoimmune projects in its research pipeline, with significant advancements in clinical trials and approvals in both China and the US [5] - The financial forecast for 2025-2027 has been adjusted, with expected revenues of 1.327 billion yuan, 1.525 billion yuan, and 1.862 billion yuan respectively, and net profits of 309 million yuan, 346 million yuan, and 452 million yuan respectively [4][7] Financial Performance Summary - In 2024, the company reported a revenue of 1.194 billion yuan, with a year-on-year growth of 17.7%. The net profit attributable to shareholders was 705 million yuan, reflecting a significant increase of 139.15% [4][7] - The projected revenue for 2025 is 1.327 billion yuan, with a year-on-year growth of 11.2%, and the net profit is expected to be 309 million yuan, a decrease of 56.2% compared to 2024 [7] - The gross margin is projected to be 73.0% in 2025, with a net margin of 23.3% [7] Research and Development Pipeline - The company has 22 autoimmune projects in its pipeline, including 1 NDA project and multiple clinical trials at various stages [5] - Key projects include SSGJ-608 for moderate to severe plaque psoriasis, SSGJ-611 for moderate to severe atopic dermatitis, and SSGJ-613 for acute gouty arthritis, all of which are progressing towards NDA submissions [5] Market Position and Valuation - The current market capitalization of the company is approximately 16.789 billion yuan, with a price-to-sales ratio projected at 12.7 for 2025 [1][4] - The company's stock has shown a trading range between 15.22 yuan and 30.30 yuan over the past year, indicating volatility in market performance [1]

Core Insights - The company reported a revenue of 1.194 billion yuan for 2024, representing a year-on-year growth of 17.7% [1] - The net profit attributable to shareholders reached 705 million yuan, showing a significant increase of 139.15% compared to the previous year [1][2] - The net cash flow from operating activities was 281 million yuan, which is a decline of 32.48% year-on-year [1] Financial Performance - The substantial increase in net profit is attributed to steady sales growth and a one-time special dividend distribution of 411 million yuan from the affiliated company Numab, which was included in the 2024 investment income [2] - The company has experienced a notable rise in sales revenue, contributing to the overall profit growth [2] Management Changes - The company announced that Sun Yongzhi will no longer serve as the financial head due to job relocation but will continue as a board member [2] - Niu Hongmei has been appointed as the new financial head, effective from the date of the board's approval until the current board's term ends [2] - Huang Haomin, a core technical staff member, has resigned from all positions within the company due to job relocation, while Gu Jinming has been recognized as a core technical personnel based on his experience and involvement in R&D projects [2][3] Key Personnel Background - Niu Hongmei, born in March 1990, holds a bachelor's degree in business administration and has experience in auditing and financial management within the company [3] - Gu Jinming, born in 1976, has a Ph.D. in molecular biology and extensive experience in R&D roles across various pharmaceutical companies [3]

Summary of the Conference Call for Sanofi Guojian Company Overview - **Company**: Sanofi Guojian - **Year**: 2024 Key Financial Performance - **Revenue**: Achieved 1.2 billion yuan, a year-on-year increase of 18% [3] - **Net Profit**: Increased significantly by 139.15%, benefiting from a special dividend from New Hope, totaling 700 million yuan [3][4] - **R&D Investment**: Invested 540 million yuan, a 72% increase year-on-year [3][4] - **Cash Reserves**: Increased to 3.3 billion yuan, indicating strong financial health [4][5] Product Performance - **Key Products**: - **Isayup**: Maintained steady revenue growth despite centralized procurement pressures, recognized by doctors and patients since 2020 [11] - **Saipulizhu**: Achieved high growth in 2024, expected to continue double-digit growth in 2025 [12][24] - **Jianipai**: Notable growth due to increased organ transplant numbers, contributing significantly to the company's revenue [13] Clinical Development and Pipeline - **Clinical Pipeline Expansion**: Increased from 8 clinical projects in 2022 to 22 in 2024 [4][6] - **Key Projects**: - **608**: Submitted NDA for plaque psoriasis, showing excellent efficacy [14][15] - **610**: Entered Phase III trials for severe eosinophilic asthma [14][16] - **613**: Positive results in Phase III for acute gouty arthritis, showing a 77% reduction in the risk of first acute gout attacks [17][18] Industry Outlook - **Chinese Innovative Drug Industry**: Transitioning from participants to leaders, supported by national health strategies and industrial policies [7] - **Autoimmune Market Potential**: Despite increasing competition, the overall market is in a rapid growth phase, requiring further exploration [7][32] Future Strategies - **Strategic Focus**: - Strengthening clinical breakthroughs and developing an AI-driven drug development platform [8] - Exploring globalization and enhancing ESG management for sustainable growth [8] - **Commercialization Plans**: Aiming to submit at least one NDA annually and maintain a robust marketing system covering thousands of hospitals [9] Management and Team Enhancements - **Team Upgrades**: Significant improvements in management and technical teams with new experienced members joining [10] Research and Development Focus - **R&D Investment**: Expected to reach 30% of revenue by 2025, focusing on early-stage research and clinical projects [29] - **IBD Market Potential**: Plans to leverage differentiated strategies in the IBD market, which is currently underdeveloped in China [30][31] Conclusion - **Overall Outlook**: Sanofi Guojian is positioned for continued growth with a strong pipeline, robust financial health, and strategic focus on innovation and market expansion. The company aims to capitalize on the growing potential of the Chinese innovative drug market, particularly in the autoimmune sector.

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 35.67 RMB [8][9]. Core Insights - The company reported a revenue of 1.19 billion RMB for 2024, representing a year-on-year increase of 17.7%, and a net profit attributable to shareholders of 705 million RMB, up 139.2% year-on-year [1]. - The company is recognized as a leader in the domestic autoimmune drug market, with a rich pipeline and strong innovation capabilities, allowing it to maintain its competitive edge [1]. - The company plans to distribute dividends amounting to 55.51 million RMB, which is 7.88% of the net profit for the year [2]. Revenue and Profit Forecast - The forecast for net profit attributable to shareholders for 2025, 2026, and 2027 is 320 million RMB, 340 million RMB, and 410 million RMB respectively, indicating a decrease of 55% in 2025, followed by increases of 6% and 20% in the subsequent years [5]. - The projected revenue for 2025 is approximately 1.38 billion RMB, reflecting a growth of 15.56% year-on-year [7]. Pipeline Development - The company has several key products in its pipeline, with 608 (IL-17) expected to submit an NDA for psoriasis in 2024, and 611 (IL-4) anticipated to read out Phase III data for adult atopic dermatitis in 2025 [3]. - The company has made significant investments in R&D, totaling 541 million RMB in 2024, which is 45% of its revenue, marking a 72% year-on-year increase [4]. Market Position and Valuation - The company is valued at approximately 17.3 billion RMB, with a P/E ratio of 24.55 for 2024 and projected to be 54.03 for 2025 [9][14]. - The average market capitalization of comparable biotech companies is around 20.3 billion RMB, indicating a premium valuation for the company based on its innovative pipeline and commercialization capabilities [5][14].

公司于 2025 年 3 月 25 日召开了第五届董事会第五次会议，审议 通过了《关于变更公司财务负责人的议案》，经公司董事会提名委员 会及董事会审计委员会对牛红梅女士的任职资格进行审查，认为其符 合《公司法》等法律法规及《公司章程》规定的相关条件，公司董事 会同意聘任牛红梅女士为公司财务负责人（简历详见附件），任期自 公司董事会审议通过之日起至本届董事会任期届满之日止。特此公 告。 附件： 牛红梅女士个人简历 三生国健药业（上海）股份有限公司 关于变更公司财务负责人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 三生国健药业（上海）股份有限公司（以下简称"公司"）近日 收到公司财务负责人孙永芝女士的书面辞职报告，因工作调动，孙永 芝女士不再担任公司财务负责人，但仍继续在公司担任董事职务，其 辞职报告自送达公司董事会之日起生效。截至本公告披露日，孙永芝 女士未持有公司股份；孙永芝女士在担任公司财务负责人期间，恪尽 职守、勤勉尽责，公司及董事会对孙永芝女士在担任财务负责人期间 为公司发展所做的贡献表示衷心感谢。 三生 ...

三生国健: 三生国健：关于公司2024年度募集资金存放与实际使用情况的专项 报告 证券代码：688336 证券简称：三生国健 公告编号：2025-012 三生国健药业（上海）股份有限公司 关于公司 2024 年度募集资金存放与实际使用情况的 专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使 用的监管要求》、《上海证券交易所科创板上市公司自律监管指引第 关规定，三生国健药业（上海）股份有限公司（以下简称"公司"或 "本公司"）董事会对 2024 年度募集资金存放与实际使用情况专项 报告说明如下： 一、募集资金基本情况 （一）实际募集资金的金额及到账时间 公司经上海证券交易所科创板股票上市委员会 2020 年 5 月 11 日 审核同意，并经中国证券监督管理委员会 2020 年 6 月 23 日《关于同 意三生国健药业（上海）股份有限公司首次公开发行股票注册的批复》 （证监许可20201217 号）注册同意，首次公开发行人民币普通股 （A 股）股票 61,6 ...

五、联系人及咨询办法 联系人：张女士 电话： （021）80297676 邮箱：ir@3s-guojian.com 六、其他事项 本次投资者说明会召开后，投资者可以通过上证路演中心 （https://roadshow.sseinfo.com/）查看本次投资者说明会的召开 情况及主要内容。 特此公告。 三生国健药业（上海）股份有限公司董事会 三生国健: 三生国健：关于召开2024年度业绩暨现 金分红说明会的公告 公司提问，公司将在说明会上对投资者普遍关注的问题进行回答。 证券代码：688336 证券简称：三生国健 公告编号：2025-018 三生国健药业（上海）股份有限公司 关于召开 2024 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 会议召开时间：2025 年 04 月 03 日（星期四）09:30-11:30 ? 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） ? 会议召开方式：上证路演中心视频直播和 ...

三生国健药业（上海）股份有限公司 关于核心技术人员变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 三生国健: 三生国健：关于核心技术人员变动的公 告 证券代码：688336 证券简称：三生国健 公告编号：2025-016 重要内容提示： ? 三生国健药业（上海）股份有限公司（以下简称"公司"或"三 生国健"）核心技术人员黄浩旻先生因工作调动申请辞去在公司担任 的所有职务，离职后黄浩旻不再担任公司任何职务。截至本公告日， 黄浩旻先生直接持有公司股份 10,230 股。 ? 黄浩旻先生工作期间作为发明人申请的相关专利所有权均归 属于公司，亦不存在涉及职务成果、知识产权相关的纠纷或潜在纠纷 的情形，黄浩旻先生的离职不影响公司专利等知识产权的完整性。 ? 黄浩旻先生在职期间负责的工作已妥善交接，其离职不会影响 公司核心技术的完整性，不会对公司生产经营带来实质性影响，不会 对公司研发实力、核心竞争力和产品创新产生不利影响。 ? 公司综合考虑未来核心技术研发方向以及研发项目的管理与 执行等实际情况，结合顾津明先生的任职履历 ...

三生国健: 三生国健：关于公司2024年度日常关联 交易执行情况及2025年度日常关联交易预计的公告 证券代码：688336 证券简称：三生国健 公告编号：2025-014 三生国健药业（上海）股份有限公司 关于公司 2024 年度日常关联交易执行情况及 2025 年 度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 是否需要提交股东大会审议：是 ? 日常关联交易对上市公司的影响：本次关联交易为公司日常关 联交易，以公司正常经营业务为基础，属于正常商业行为，遵守了自 愿、等价、有偿的原则，定价公平合理，不影响公司的独立性，不存 在损害公司及股东利益的情形，公司不会因该关联交易对关联人产生 依赖。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 三生国健药业（上海）股份有限公司（以下简称"公司"或"三 生国健"）于 2025 年 3 月 25 日召开第五届董事会独立董事专门会议 第二次会议，审议通过了《关于公司 2024 年度日常关联交易执行情 况及 2025 年度日常 ...

三生国健: 三生国健：关于安永华明会计师事务所 （特殊普通合伙）履职情况的评估报告 三生国健药业（上海）股份有限公司 关于安永华明会计师事务所（特殊普通合伙）履职 情况的评估报告 三生国健药业（上海）股份有限公司（以下简称"公司"）聘 请安永华明会计师事务所（特殊普通合伙）（以下简称"安永华 明"）作为对公司2024年度财务报告出具审计报告的会计师事务所。 根据财政部、国务院国有资产监督管理委员会、中国证券监督 管理委员会颁布的《国有企业、上市公司选聘会计师事务所管理办 法》，公司对安永华明在2024年度的审计工作的履职情况进行了评 估。具体情况如下： 一、2024年年审会计师事务所基本情况 安永华明近三年因执业行为受到刑事处罚0次、行政处罚0次、 监督管理措施3次、自律监管措施0次、纪律处分0次。13名从业人员 近三年因执业行为受到刑事处罚0次、行政处罚1次、监督管理措施4 次、自律监管措施1次和纪律处分0次；2名从业人员近三年因个人行 为受到行政监管措施各1次，不涉及审计项目的执业质量。根据相关 法律法规的规定，上述事项不影响安永华明继续承接或执行证券服 务业务和其他业务。 （一）会计师事务所基本情况 安 ...